TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01049386

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: No intervention
Description: In obese and lean subjects the intestinal absorption will be examined under normal conditions with sugar drink, and when disturbed by a high-fat breakfast.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: No intervention
Description: In obese and lean subjects the intestinal absorption will be examined under normal conditions with sugar drink, and when disturbed by a high-fat breakfast.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Sugar absorption test
Description: On one of the test days the subjects will consume a high-fat breakfast.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sugar absorption test
Description: On one of the test days the subjects will consume a high-fat breakfast.
Study: NCT02807961

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ELX-02
Description: Synthetic aminoglycoside

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo comparator
Study: NCT01028755

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY79-4620
Description: BAY79-4620 will be administered as 1 hour IV infusion. Dose escalation will be dependent on any dose limiting toxicities
Study: NCT02668198

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Olympus CF190 Colonoscope High definition white light
Description: Standard endoscopic imaging technique

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Olympus CF190 Colonoscope White light with near focus
Description: Near focus mode is used to closely examine the area of prior EMR site.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Olympus CF190 Colonoscope Narrow band imaging
Description: Narrow band imaging is utilized to examine the area of prior EMR.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Olympus CF190 Colonoscope Narrow band imaging with near focus
Description: NBI with near focus to help closely examine the area of prior EMR site.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Biopsy to assess any evidence of residual neoplasia via standard histopathology assessment
Study: NCT01268098

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NPSP558
Description: All patients will inject NPSP558 25 or 50 µg SC QD into alternating thighs in the morning via a multidose injection pen device.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NPSP558
Description: All patients will inject NPSP558 25 or 50 µg SC QD into alternating thighs in the morning via a multidose injection pen device.
Study: NCT00817245

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: omeprazole, Amoxicillin, metronidazole
Description: we will evaluate the effect of medication(anti h.pylori) on the remission of ICSCR
Study: NCT04219878

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Know@Home
Description: Participants randomly assigned to the Know@Home arm will access the features of Know@Home by downloading the app or accessing the website. The contents were developed to serve as a comprehensive mobile HIV prevention platform for MSM or TGW, with HIV prevention and care information and links to resources. This intervention arm provides an toolkit that allows users to access information about prevention services as their needs change. Participants will have access to Know@Home for the study period. The Know@Home arm will offer participants the opportunity to order free condoms and lubricant as well as an at-home sexually transmitted infection (STI) testing kit.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Self-test Kit
Description: All participants will be shipped two at-home HIV self-tests. They will also receive a link to a previously-produced video that fully describes the specimen collection process, pointing out common errors and providing tips for successful collection. Participants will interact with study staff through phone, email, or text. Information to schedule a video HIV testing and counseling session with study staff will be made available to participants in all arms via a website, email, and/or text.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Self-test Kit
Description: All participants will be shipped two at-home HIV self-tests. They will also receive a link to a previously-produced video that fully describes the specimen collection process, pointing out common errors and providing tips for successful collection. Participants will interact with study staff through phone, email, or text. Information to schedule a video HIV testing and counseling session with study staff will be made available to participants in all arms via a website, email, and/or text.
Study: NCT01584011

Intervention type: OTHER
Intervention: taste measurement
Description: Taste measurements with Electrogustometry and Filter paper test before and after surgery until one year after surgery

Intervention type: OTHER
Intervention: Symptom questionnaire
Description: Answering a symptom questionnaire before and after surgery until one year after surgery

Intervention type: BEHAVIORAL
Intervention: Quality of life questionnaire
Description: Answering a quality of life questionnaire before and one year after surgery

Intervention type: OTHER
Intervention: Nerve sample
Description: Collect nerve samples from patients undergoing surgery because of vestibular schwannoma, chronic otitis media or cholesteatoma where the nerve cant be saved during planned operation.
Study: NCT03602248

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Speed endurance training protocol A
Description: 1 set of 8 repetitions interspersed by 2,5 minutes of recovery with a work to rest ratio of 1:5 (25-30 seconds all out work)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Speed endurance training protocol B
Description: 1 set of 8 repetitions interspersed by 4 minutes of recovery with a work to rest ratio of 1:8 (25-30 seconds all out work)
Study: NCT03215342

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pediatric Goal Management Training
Description: 7 GMT modules will be administered in 7x2 hours sessions (ten groups). Manualized intervention; metacognitive strategies for improving attention and problem solving. Homework assignments between sessions.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pediatric Brain Health Workshop
Description: 7 pBHW modules will be administered in 7x2 hours sessions (ten groups). Psychoeducation; brain (dys)function, plasticity, memory, executive function, and attention. Stress, physical exercise, sleep, nutrition, and energy management. Homework assignments between sessions
Study: NCT01722045

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravitreal Aflibercept Injection (IAI)
Study: NCT04332432

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: belapectin
Description: intravenous
Study: NCT04505475

Intervention type: PROCEDURE
Intervention: Oral surgical procedure followed by local hemostatic measures (insertion of gelatine sponge and wound suturing)
Description: single and multiple teeth extraction, surgical tooth extraction, third molar surgery, gingivectomy, soft-tissue biopsy

Intervention type: PROCEDURE
Intervention: Oral surgical procedure followed by local hemostatic measures (insertion of gelatine sponge and wound suturing)
Description: single and multiple teeth extraction, surgical tooth extraction, third molar surgery, gingivectomy, soft-tissue biopsy
Study: NCT03921242

Intervention type: DRUG
Intervention: Metformin
Description: Newly Initiated and regular metformin dosage as prescribed by each patient's medical care provider

Intervention type: DRUG
Intervention: Sulfonylurea
Description: Newly initiated and regular sulfonylurea dosage as prescribed by each patient's medical care provider

Intervention type: DRUG
Intervention: DPP-4 inhibitor
Description: Newly initiated and regular DPP-4 inhibitor dosage as prescribed by each patient's medical care provider

Intervention type: DRUG
Intervention: SGLT2 inhibitor
Description: Newly initiated and regular SGLT2 inhibitor dosage as prescribed by each patient's medical care provider

Intervention type: DRUG
Intervention: GLP1 receptor agonist
Description: Newly initiated and regular GLP1 receptor agonist dosage as prescribed by each patient's medical care provider
Study: NCT02990923

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High-Flow Needleless Valve

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High-Flow Needleless Valve

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DualCap Disinfection Devices
Study: NCT01644188

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alirocumab
Description: 1 mL subcutaneous injection in the abdomen, thigh, or outer area of the upper arm by self-injection or by another designated person using the autoinjector.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo (for alirocumab)
Description: 1 mL subcutaneous injection in the abdomen, thigh, or outer area of the upper arm by self-injection or by another designated person using the autoinjector.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ezetimibe
Description: One over-encapsulated tablet orally once daily at approximately the same time of the day with or without food.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo (for ezetimibe)
Description: One capsule once daily orally at approximately the same time of the day with or without food.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lipid Modifying Therapy (LMT)
Description: Statin (rosuvastatin, simvastatin or atorvastatin) at stable dose.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lipid Modifying Therapy (LMT)
Description: Statin (rosuvastatin, simvastatin or atorvastatin) at stable dose.
Study: NCT02999737

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Platelet Rich Plasma for 4 sessions
Description: Injection of autologous platelet rich plasma into areas of alopecia on the scalp every month x 3 sessions then every 3 months x 1 session (total 4 sessions)

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Platelet rich plasma for 2 sessions
Description: Injection of autologous platelet rich plasma into areas of alopecia on the scalp every 3 months x 2 sessions (total 2 sessions)
Study: NCT04605198

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Modified Mindfulness-based Stress Reduction
Description: Participants will be trained in mindfulness meditation and the applicability of mindfulness practices to daily life. During MBSR programming, teachers will lecture about key topics in mindfulness and lead class discussions. Participants are given homework assignments, such as listening to guided meditations. Participants are given opportunities to ask the instructor questions and to share their experiences with each other. Each session focuses on a different key topic. Topics are: Session 1: Introduction; Session 2: Understanding Perceptions; Session 3: Hatha Yoga, Sitting Meditation, Walking Meditation; Session 4: Concentration \& Awareness; Session 5: Unhealthy Patterns \&Getting Unstuck; Session 6: Transformational Coping Strategies; Session 7: Mini-retreat; Session 8: Maintaining Discipline \& Flexibility; Session 9: Course Review.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Health Promotion Wellness Classes
Description: Sessions will cover the following general wellness topics: Session 1; Introduction; Session 2: Envisioning Health Through Art; Session 3: Chronic Disease 1 (Heart Health); Session 4: Chronic Disease II (Diabetes); Session 5: Nutrition and Hydration; Session 6: Infectious Disease Prevention; Session 7: Skin Care; Session 8: Oral Health; Session 9: Promoting Social Integration \& Course Graduation.
Study: NCT01042717

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Plerixafor
Description: Plerixafor administered at 16 hours prior to apheresis
Study: NCT04224259

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ultrasound pre-scan
Description: Before cannulation, use ultrasound to mark the position of right internal jugular vein

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Landmark guidance
Description: The traditional landmark-guided technique for internal jugular vein cannulation, including recognizing the sternocleidomastoid muscle and palpating the carotid artery
Study: NCT04338230

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Progressive muscle relaxation exercise
Description: Relaxation Exercises CD Audio Records prepared by Turkish Psychological Association is used. Before starting the PMR exercises, the woman in the intervention group is provided to lie on a comfortable seat or bed, stretching the muscles of the face and all body for about 10 seconds starting from the hands to the foot in line with the sound recordings of the PKG exercises and then holding the deep breath while each muscle group is stretching, It is applied as a slow release of this breath during relaxation. In this way, the muscle groups in the hands, arms, neck, shoulders, chest, abdomen, hips, feet and fingers, the face and the whole body are tensioned and relaxed, and the woman is relaxed. During the eight-week period, the women are called by the researcher once a week and the exercises are reminded. Home visit There are 2 home visits at week 1 and at week 8. In case of need, repeated home visits are provided to ensure the continuity of the application.
Study: NCT01628406

Intervention type: PROCEDURE
Intervention: Treatment at the neurosurgery departement
Description: Treatment at the neurosurgery departement
Study: NCT03181919

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole
Description: Letrozole is a third generation inhibitor that is emerging as a new oral agent for induction of ovulation.
Study: NCT03479125

Intervention type: DIAGNOSTIC_TEST
Intervention: Ultrasound
Description: Subjects will be observed to estimate the adjusted event rate for hepatocellular carcinoma with or without cirrhosis previously treated with emricasan or placebo.
Study: NCT03477409

Intervention type: OTHER
Intervention: plasticizers
Description: The purpose of this biomonitoring study consists to evaluate the exposure of newborns and premature babies hospitalized in NICU to these plasticizers (DEHT and TOTM), by qualitative and quantitative measurement of their urinary metabolites
Study: NCT02392663

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Hypertonic saline solution
Description: All patients will perform 4 sessions during the same week. Each session will be include: inhalation period + bronchial drainage period. 20 minutes will be spent to perform the inhalation period. Moreover, 30 minutes will be spent to complete the bronchial drainage session post-inhalation.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Hyaneb solution
Description: All patients will perform 4 sessions during the same week. Each session will be include: inhalation period + bronchial drainage period. 20 minutes will be spent to perform the inhalation period. Moreover, 30 minutes will be spent to complete the bronchial drainage session post-inhalation.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Isotonic saline solution
Description: All patients will perform 4 sessions during the same week. Each session will be include: inhalation period + bronchial drainage period. 20 minutes will be spent to perform the inhalation period. Moreover, 30 minutes will be spent to complete the bronchial drainage session post-inhalation.
Study: NCT02371720

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mobile DOT
Description: Daily reminders via text or email to send a video of themselves taking their Hydroxyurea, positive feedback, and be encouraged to contact the research coordinator with any questions, concerns, etc.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mobile DOT
Description: Daily reminders via text or email to send a video of themselves taking their Hydroxyurea, positive feedback, and be encouraged to contact the research coordinator with any questions, concerns, etc.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mobile DOT
Description: Daily reminders via text or email to send a video of themselves taking their Hydroxyurea, positive feedback, and be encouraged to contact the research coordinator with any questions, concerns, etc.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mobile DOT
Description: Daily reminders via text or email to send a video of themselves taking their Hydroxyurea, positive feedback, and be encouraged to contact the research coordinator with any questions, concerns, etc.
Study: NCT01885923

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ITAREPS
Description: Program ITAREPS (Information Technology Aided Relaps Prevention in Schizophrenia)
Study: NCT00003693

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dolastatin 10
Description: IV bolus once every 3 weeks.
Study: NCT01625676

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Investigate efficacy of modified ciat schedule
Description: 2 hours of training over 15 days

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: examine the efficacy of standard treatment versus modified ciat schedule
Description: 2 hours of training over 15 days
Study: NCT03977571

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cytoreductive nephrectomy
Description: Partial or complete nephrectomy by open, laparoscopic, or robotic approach.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tissue sampling
Description: Tumor biopsies, blood, and stool specimens for translational biomarker research will be sampled at baseline and after 3 or 6 months.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Tissue sampling
Description: Tumor biopsies, blood, and stool specimens for translational biomarker research will be sampled at baseline and after 3 or 6 months.
Study: NCT03299127

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: imagery rescripting
Description: The long version of the manual contained 4,959 words, the brief version had 3,369 words. Individuals were encouraged patients to time travel to negative personal events, enter the scene and protect or comfort their younger-ego. The participant should bring the negative event to a happy end. This could also be a fictive, compassionate person and may violate the laws of physics (e.g., a person may fly). Readers were encouraged to embellish the scenes as much as possible so that it competed with the original scene. This technique was then applied to future events. For the last technique, patients were asked to seek a corresponding mood-congruent metaphor, creature or symbol; for example, a small bird that has fallen out of its nest. Using their mind's eye, these images may be transformed into something of beauty or pride.
Study: NCT01951378

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Hudson RCI® nebulizer
Description: After the first hour of treatment, patients in the standard arm will receive a repeat assessment, including all of the measurements collected at baseline as well as reported side effects. Those patients who score PAS 0-2 will then be discharged home, after an optional observation period, as per the pathway. Those who score PAS \> 2 will receive a second treatment. At the end of the second treatment patients will again be re-assessed, and repeat measurements obtained. At that time, depending on the patient's PAS score, he/she will be dispositioned to home, the floor, the pulmonary high acuity unit (PHAU), or the pediatric intensive care unit (PICU).

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: NebuTech® HDN® nebulizer
Description: All treatments in the NebuTech® arm will be given at a standard dilution of 5 ml (diluted with normal saline to a total volume of 5 ml as per the manufacturer's recommendation). Patients in this arm will receive up to four treatments with parameters measured after each treatment, similar to the control arm. Patients who complete four treatments will then be dispositioned based on PAS score, similar to the control arm. Subjects may have started treatment prior to consent and may receives unit dose (2.5 mg) Albuterol/Proventil treatments will be given with a standard nebulizer up to 3 times as needed and may change over to study randomized device once consented to eith arm.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Albuterol
Description: Subjects may have started treatment prior to consent and may receives unit dose (2.5 mg) Albuterol/Proventil treatments will be given with a standard nebulizer up to 3 times as needed and may change over to study randomized device once consented to eith arm.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Albuterol
Description: Subjects may have started treatment prior to consent and may receives unit dose (2.5 mg) Albuterol/Proventil treatments will be given with a standard nebulizer up to 3 times as needed and may change over to study randomized device once consented to eith arm.
Study: NCT05019313

Intervention type: DEVICE
Intervention: Evaluation of diaphragmatic contractility by ultrasound
Description: Lung ultrasound is performed during mechanical ventilation weaning. The diaphragmatic thickening fraction is evaluated positioning a linear probe in midaxillary line. Inspiratory and expiratory measurements are bilateral and are M-mode images. Right diaphragmatic thickening fraction has been considered as true and reproducible measurement.
Study: NCT02624869

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Evolocumab
Description: Administered by subcutaneous injection
Study: NCT02813213

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Skin micro Grafts
Description: 0.8 x 0.8 skin micro graft with graft to graft distance of 4 cm (1:50 expansion) bathed with keratinocyte growth factor solution ( 1.5 ml for each 14 square centimeters of wound)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard skin graft
Description: Standard split thickness (0.3-0.5mm) skin graft
Study: NCT03647384

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gulingji capsules
Description: Patients take 0.6g of Gulingji capsules, 2 hours before breakfast, served with light salt water once a day. Also an oral take of 19.2mg Ginko Biloba Extract mimetic three times a day. Treatment lasts for 24 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ginko Biloba Extract tablet
Description: Patients take 0.6g of Gulingji mimetic, 2 hours before breakfast, served with light salt water once a day. Also an oral take of 19.2mg Ginko Biloba Extract tablet three times a day. Treatment lasts for 24 weeks.
Study: NCT04038320

Intervention type: DRUG
Intervention: Sofosbuvir/ledipasvir (SOF/LDV)
Description: SOF/LDV (400mg/90mg) orally once daily with or without food in the morning and will receive treatment for a duration of 12 weeks.~In addition, Ribavirin weight-based (1000 mg for patients \<75 kg and 1200 mg for those ≥75 kg) administered orally in two divided doses with food for Genotype 3 patients.